Home Tags Tumor heterogeneity
Tag: Tumor heterogeneity
Advances in the Development of Dual-Drug Antibody Drug Conjugates
Antibody drug conjugates (ADCs) are touted for their ability to site selectively deliver a small molecule chemotherapeutic directly to a tumor cell, bypassing off target side effects from systemic circulation. To date, eleven ADCs have been FDA approved in the United States and >200 more in the clinical pipeline (clinicaltrials.gov).